Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Marina A. Malikova"'
Autor:
Veronique Kugener, Karine Palin, Maribel Salas, Peggy Webster, Abimbola Cole, John Price, Sepideh Habibi, Christa Naboulet, Dona Ely, Pinak Joshi, Marina A. Malikova
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/c911a8d681f143438eab6e39f1e3dfd0
Autor:
Marina A. Malikova, Gianluca Trifirò, Giorgio Racagni, Dennis Van Liew, Peggy Webster, Tejal S. Brahmbhatt
Publikováno v:
Frontiers in Drug Safety and Regulation, Vol 2 (2022)
Externí odkaz:
https://doaj.org/article/56ac5fcf95c34c289bb074129a75573c
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 13 (2022)
The COVID-19 pandemic, caused by a novel type of coronavirus, continues to infect people, increasing morbidity and mortality across the globe. Measures to slow the transmission of the virus have had limited impact, and people, businesses, and economi
Externí odkaz:
https://doaj.org/article/ab596e33c18d446bbd2f126f4707f6eb
Autor:
Marina A. Malikova
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 11 (2020)
Pharmacovigilance is a field where communication is crucial, and exchange of information is expected to be done in a timely manner. Information from individual case reports is transmitted from pharmaceutical industry and health professionals to the r
Externí odkaz:
https://doaj.org/article/6a81ae8b4c1c47c4ba4e5b2afe54d8de
Publikováno v:
Therapeutic advances in drug safety. 13
The COVID-19 pandemic, caused by a novel type of coronavirus, continues to infect people, increasing morbidity and mortality across the globe. Measures to slow the transmission of the virus have had limited impact, and people, businesses, and economi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7800d4268271f9d67073da238365625f
https://pubmed.ncbi.nlm.nih.gov/36072284
https://pubmed.ncbi.nlm.nih.gov/36072284
Autor:
Marina A Malikova, A O Kaliaev
Publikováno v:
Therapeutic innovationregulatory science. 54(4)
Newly emerging products which combine drugs, devices, and biologics are expected to provide new opportunities in bridging device and drug capabilities and establish synergies while bringing sophisticated combination products to consumers. The emergen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9513b104cb175cab1a50e9826015dd40
https://pubmed.ncbi.nlm.nih.gov/32557305
https://pubmed.ncbi.nlm.nih.gov/32557305
Autor:
Marina A Malikova
Publikováno v:
International Journal of Clinical Trials. 8:79
The coronavirus disease 2019 (COVID- 19) pandemic is disrupting clinical research in most of the world. We have seen an immediate impact on clinical trials due to challenges coming from the COVID-19 travel bans, hospitals/clinics’ visitation restri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c036afe3ba6519fb85ffaccf9bc337a
https://doi.org/10.18203/2349-3259.ijct20210148
https://doi.org/10.18203/2349-3259.ijct20210148
Autor:
Marina A Malikova
Publikováno v:
Future Science OA
Advances in Medical Biochemistry, Genomics, Physiology, and Pathology ISBN: 9781003180449
Advances in Medical Biochemistry, Genomics, Physiology, and Pathology ISBN: 9781003180449
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f1ebc6cc99c7aa44a58cff72d65d99
http://europepmc.org/articles/PMC6088261
http://europepmc.org/articles/PMC6088261
Publikováno v:
Clinical Investigation. 5:653-664
Background: Clinical trials are designed to test efficacy and safety of new drugs. Trials testing biologics for wound care is a fast growing field. We have analyzed clinical trials testing fibroblast cell-based agents for chronic venous stasis ulcers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cedcd4946d15685c4a2f2cef49322730
https://doi.org/10.4155/cli.15.30
https://doi.org/10.4155/cli.15.30
Autor:
Philip P. Goodney, Gheorghe Doros, Marina A Malikova, Jens Elderup-Jorgenson, Jack L. Cronenwett, Mohammad H. Eslami, Alik Farber
Publikováno v:
Annals of Vascular Surgery. 29:278-285
Background We describe the organization of a prospective, randomized, multicenter trial comparing the effectiveness of open popliteal artery aneurysm repair (OPAR) and endovascular popliteal artery aneurysm repair (EPAR) of asymptomatic popliteal art
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7376c2e83f8f4428d4c961f39cceae4
https://doi.org/10.1016/j.avsg.2014.08.007
https://doi.org/10.1016/j.avsg.2014.08.007